Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Novartis Investigative Site 01307 Dresden (Sachsen) GermanyZurückgezogen» Google-MapsNovartis Investigative Site 30625 Hannover (Niedersachsen) GermanyRekrutierend» Google-MapsNovartis Investigative Site 50937 Koeln (Nordrhein-Westfalen) GermanyRekrutierend» Google-Maps
Massachusetts General Hospital MGH Cancer Center 02114 Boston United StatesRekrutierend» Google-Maps Ansprechpartner: Julia K Digiovanni E-Mail: JKDigiovanni@mgh.harvard.edu» Ansprechpartner anzeigenNovartis Investigative Site 3000 Leuven BelgiumRekrutierend» Google-MapsNovartis Investigative Site T6G 1Z2 Edmonton CanadaAbgeschlossen» Google-MapsNovartis Investigative Site DK-2100 Copenhagen DenmarkAbgeschlossen» Google-MapsNovartis Investigative Site 21034 Dijon FranceAbgeschlossen» Google-MapsNovartis Investigative Site 20141 Milano ItalyRekrutierend» Google-MapsNovartis Investigative Site 06129 Perugia ItalyRekrutierend» Google-MapsNovartis Investigative Site 03080 Seoul Korea, Republic ofRekrutierend» Google-MapsNovartis Investigative Site 05505 Seoul Korea, Republic ofZurückgezogen» Google-MapsNovartis Investigative Site 05505 Seoul Korea, Republic ofRekrutierend» Google-MapsNovartis Investigative Site 119074 Singapore SingaporeRekrutierend» Google-MapsNovartis Investigative Site 28040 Madrid SpainAbgeschlossen» Google-Maps
1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability (Time Frame - Day 1 up to 10 years, assessed every 12 weeks): Collection of adverse events and serious adverse events at every visit. Safety assessment will be performed and include local laboratory test monitoring in addition to local standard of care assessments.
Experimental: Capmatinib Starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
Experimental: Capmatinib + Nazartinib Starting dose of the study treatment for patients should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
Experimental: Capmatinib + Gefitinib Starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
Experimental: Capmatinib + Osimertinib Starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
Capmatinib (INC280): Tablet for oral use; 150 mg, 200 mg; twice a day
Nazartinib (EGF816): Capsule for oral use; 25 mg, 50 mg; once a day
Gefitinib: tablets for oral use; 250mg; once a day
Osimertinib: Tablets for oral use; 40 mg, 80 mg; once a day.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!